SS
DNTH icon

SBI Securities’s Dianthus Therapeutics DNTH Stock Holding History

SBI Securities’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76K Buy
21
+19
+950% +$1.1K ﹤0.01% 2461
2025
Q4 		$82 Hold
2
– – ﹤0.01% 3464
2025
Q3 		$79 Buy
2
+1
+100% +$26 ﹤0.01% 3585
2025
Q2 		$19 Hold
1
– – ﹤0.01% 3922
2025
Q1 		$18 Sell
1
-6
-86% -$132 ﹤0.01% 3871
2024
Q4 		$153 Buy
+7
New +$180 ﹤0.01% 3331

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SBI Securities's DNTH Position: Q1 2026 in Review

SBI Securities increased its Dianthus Therapeutics (DNTH) stake by 950% in Q1 2026, buying an estimated $1.1K and bringing the position to 21 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

SBI Securities first reported a position in DNTH in Q4 2024 and has held it in 6 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • SBI Securities held 21 shares of Dianthus Therapeutics worth $1.76K as of Q1 2026.
  • SBI Securities bought 19 Dianthus Therapeutics shares in Q1 2026, an estimated $1.1K.
  • Dianthus Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2461 holding.
  • SBI Securities first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.